Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Metabomed, a Cancer Metabolism Specialist, Closes $12.5 Million Financing Led by Yonjin Venture

publication date: Dec 19, 2019

Metabomed, an Israeli company developing cancer therapies based on inhibiting cancer metabolism, closed a $12.5 million financing led by Yonjin Venture, a division of Shanghai's Yonjin Group. Metabomed also named its first clinical candidate, a first-in-class program that inhibits AcetylCoA Short chain Synthase 2 enzyme in cancers dependent on acetate metabolism. The company has developed a platform using computational biology, genomics and metabolomics to identify small molecule targets that stop the growth of the metabolic structure supporting the cancer. To date, Metabomed has raised $30 million. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital